MentionFox
Home › Executive changes › C4 Therapeutics, Inc.
Leadership changes · CCCC · SEC Form 8-K, Item 5.02

Leadership changes at C4 Therapeutics, Inc. (2026)

Before you join, sell to or invest in C4 Therapeutics, Inc.

MentionFox check on C4 Therapeutics, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/c4-therapeutics

  • Note: Layoff plan disclosed Jan 2024 (about 45 employees) (filing)

New since last check: Layoff plan disclosed Jan 2024 (about 45 employees) (filing, first seen 14 November 2026).

Check C4 Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about C4 Therapeutics, Inc.?

Who joined and who left C4 Therapeutics, Inc. (CCCC)? 1 filing reported on 2026-05-15, each cited to the company's own filing.

As of November 14, 2026, C4 Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 15, 2026 (Form 8-K, May 15, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies ↓

Sell to companies like C4 Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-05-15

C4 Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-15. Every row below is cited to the filing it comes from, and this page adds each new change as C4 Therapeutics, Inc. files it.

Layoffs on record: about 45 jobs, latest 2024-01-09 (layoff filings and notices).

Also on the record for C4 Therapeutics, Inc.

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G/A, by Lynx1 Capital Management LP9.99% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by RA Capital Management, L.P.9.9% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Squadron Master Fund LP6.9% of the class5%+ stakesSource
August 12, 2026Stake report, Schedule 13G/A, by Morgan Stanley8% of the class5%+ stakesSource
July 27, 2026Stake report, Schedule 13G, by BlackRock, Inc.6.9% of the class5%+ stakesSource
May 19, 2026Stake report, Schedule 13G, by Squadron Master Fund LP5% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by Sirenia Capital Management LP9.9% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Point72 Asset Management, L.P.0.2% of the class5%+ stakesSource
April 22, 2026Stake report, Schedule 13G/A, by Wasatch Advisors LP4.7% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Lynx1 Capital Management LP7.3% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by OrbiMed Capital LLC1% of the class5%+ stakesSource
February 12, 2026Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P.9.99% of the class5%+ stakesSource

Selling to them or working with them? See who runs C4 Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on C4 Therapeutics, Inc. and the records around it.

C4 Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on C4 Therapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on C4 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on C4 Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 20 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-05-15Reportednot named in the filing8-K, 2026-05-15
Selling to C4 Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on C4 Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch C4 Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at C4 Therapeutics, Inc., with the record behind each one.

Find candidates like senior executive at C4 Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-05-15 · 8-K

Reported

Mr. Mossler's departure from the Company is not due to any disagreement with the Company or the Company's Board of Directors on any matter relating to the Company's financial reporting, operations, policies or practices.

Also stated in this filing

  • Departure of Principal Accounting Officer On May 12, 2026, C4 Therapeutics, Inc. (the "Company") determined that Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.
  • Appointment of Principal Accounting Officer Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.
  • Ms. Adams will not receive any additional compensation for assuming the additional role of principal accounting officer, and no changes have been made to any plans or arrangements in which Ms. Adams participates as a result of this appointment.

Tools for this story

Each opens in a new tab, filled in for C4 Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/c4-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of C4 Therapeutics, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/c4-therapeutics